Atevirdine

Atevirdine

Atevirdine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that was under development for the treatment of HIV and AIDS. It was developed by Pharmacia & Upjohn but its development was discontinued in the late 1990s due to poor clinical results.

History

Atevirdine was first synthesized in the early 1990s as part of a research program by Pharmacia & Upjohn to develop new treatments for HIV and AIDS. The drug was designed to inhibit the reverse transcriptase enzyme, which is crucial for the replication of the HIV virus.

Mechanism of Action

Atevirdine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). NNRTIs work by binding to the reverse transcriptase enzyme, preventing it from converting viral RNA into DNA. This stops the virus from replicating and spreading to new cells.

Clinical Trials

Atevirdine underwent several phases of clinical trials in the 1990s. However, the results were disappointing. The drug was found to be less effective than other NNRTIs, and it had a high rate of side effects, including rash and liver toxicity. As a result, Pharmacia & Upjohn decided to discontinue the development of the drug.

Legacy

Despite the failure of Atevirdine, the research program that produced it contributed to the development of other NNRTIs that have been successful in treating HIV and AIDS. These include Efavirenz, Nevirapine, and Delavirdine.

See Also

• Non-nucleoside reverse transcriptase inhibitor
• Pharmacia & Upjohn
• Efavirenz
• Nevirapine
• Delavirdine

This HIV related article is a stub. You can help WikiMD by expanding it.

This article is a stub related to pharmacology. You can help WikiMD by expanding it!